ongoing

ANNEXa-1 is a randomized, multicenter, Phase 4 clinical trial of 440 patients designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracranial hemorrhage.

Study Type

Interventional - Drug

Study Design

Prospective open-label RCT

NO. of Countries

10

NO. of Sites

100

NO. of Participants

440

Study Period

2019 - 2022

Sponsor

Portola Pharmaceuticals

Portola Pharmaceuticals, Inc.

Back To Top